Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL21P133 (ribosomal protein L21 pseudogene 133) is a processed pseudogene that shares sequence similarity with the ribosomal protein L21 gene but does not encode a functional protein. Pseudogenes like RPL21P133 are typically non-coding remnants of ancestral genes dispersed throughout the genome, without physiological roles, and are not considered valid therapeutic targets or biomarkers[4][1]. For biological and pharmacological purposes, the protein-coding analog "ribosomal protein L21" (RPL21) is associated with protein synthesis and disease (e.g., hypotrichosis simplex of the scalp), but RPL21P133 pseudogene itself has no such activity or clinical relevance[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 133 (RPL21P133).